文献速递皮肤肿瘤

高剂量维生素D补充未能改善皮肤黑色素瘤患者结局:ViDMe随机双盲安慰剂对照试验

High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial).
PubMed 文献 · Br J Dermatol · 2024-01-01

中位随访52个月,补充组25-羟基维生素D水平显著升高,但无复发生存率、黑色素瘤相关死亡及总生存均无显著改善。

要点

  • 每月10万IU维生素D补充安全,但未改善无复发生存。
  • 补充组72个月无复发生存事件率为26.51%,安慰剂组为20.70%,差异无统计学意义。
  • 不推荐为改善黑色素瘤结局而常规补充高剂量维生素D。

核心结论

  • 在已切除的皮肤黑色素瘤患者中,每月高剂量维生素D补充安全且能持续提升25-羟基维生素D水平,但未改善无复发生存、黑色素瘤相关死亡或总生存。

研究设计与样本

  • 随机化后中位随访52个月,最长随访116个月,主要终点为无复发生存。

主要发现

  • 补充6个月后,治疗组25-羟基维生素D血清水平中位升高17 ng mL-1(95% CI 9-26),安慰剂组为0 ng mL-1(95% CI 6-8),P < 0.001(Wilcoxon检验)。
  • 入组后72个月无复发生存估计事件率:维生素D补充组为26.51%(95% CI 19.37-35.64),安慰剂组为20.70%(95% CI 14.26-29.52),风险比1.27(95% CI 0.79-2.03;P = 0.32)。
  • 调整混杂因素(包括基线分期、体重指数、年龄、性别和基线季节)后,风险比为1.20(95% CI 0.74-1.94,P = 0.46)。
  • 黑色素瘤进展死亡人数在维生素D补充组和安慰剂组分别为10例和11例,非黑色素瘤相关死亡分别为3例和2例。
  • 研究期间未观察到重大不良事件。

临床怎么用

  • 基于本研究,不推荐为改善黑色素瘤结局而对已切除的皮肤黑色素瘤患者常规补充高剂量维生素D。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies in cutaneous melanoma (CM) have indicated an inverse relationship between levels of 25-hydroxyvitamin D and Breslow thickness, in addition to a protective effect of high 25-hydroxyvitamin D levels on clinical outcome. OBJECTIVES: To evaluate whether high-dose vitamin D supplementation in curatively resected CM reduces melanoma relapse. METHODS: In a prospective randomized double-blind placebo-controlled trial, 436 patients with resected CM stage IA to III (8th American Joint Committee on Cancer staging) were randomized. Among them, 218 received a placebo while 218 received monthly 100 000 IU cholecalciferol for a minimum of 6 months and a maximum of 42 months (treatment arm). Following randomization, patients were followed for a median of 52 months, with a maximum follow-up of 116 months. The primary endpoint was relapse-free survival. Secondary endpoints were melanoma-related mortality, overall survival, and the evolution of 25-hydroxyvitamin D serum levels over time. RESULTS: In our population (mean age 55 years, 54% female sex) vitamin D supplementation increased 25-hydroxyvitamin D serum levels after 6 months of supplementation in the treatment arm by a median 17 ng mL-1 [95% confidence interval (CI) 9-26] compared with 0 ng mL-1 (95% CI 6-8) in the placebo arm (P < 0.001, Wilcoxon test) and remained at a steady state during the whole treatment period. The estimated event rate for relapse-free survival at 72 months after inclusion was 26.51% in the vitamin D supplemented arm (95% CI 19.37-35.64) vs. 20.70% (95% CI 14.26-29.52) in the placebo arm (hazard ratio 1.27, 95% CI 0.79-2.03; P = 0.32). After adjusting for confounding factors (including baseline stage, body mass index, age, sex and baseline season), the hazard ratio was 1.20 (95% CI 0.74-1.94, P = 0.46). The number of deaths from progression of CM and nonmelanoma-related deaths was similar in both the vitamin D supplemented and placebo groups (deaths from progression of CM, n = 10 and n = 11, respectively; nonmelanoma-related deaths, n = 3 and n = 2, respectively). No major adverse events were observed during the study. CONCLUSIONS: In patients with CM, monthly high-dose vitamin D supplementation was safe, resulted in a sustained increase in 25-hydroxyvitamin D levels during the treatment period, but did not improve relapse-free survival, melanoma-related death or overall survival. Cutaneous melanoma (CM) is the most lethal form of skin cancer. Previous studies have shown that low vitamin D (VD) levels in the blood at the time of CM diagnosis are associated with thicker tumours, and a worse outcome. The aim of this study was to examine whether monthly high-dose VD supplementation after diagnosis and surgical treatment of a primary melanoma could improve outcomes. We carried out a clinical trial that included 436 patients with CM who were randomly allocated into two groups. One group of 218 patients received a placebo (an inactive treatment) and another group of 218 patients received a monthly oral oil solution containing VD (known as the treatment group). We looked at relapse-free survival, levels of melanoma-related mortality, overall survival, and the evolution of VD levels over time, and compared the results for both groups. We found that monthly high-dose VD supplementation was safe, but did not protect against recurrence of CM or risk of death. Therefore, based on our study findings, we do not recommend high-dose VD supplementation for people with CM to improve melanoma outcomes.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. De Smedt J, Van Kelst S, Janssen L, et al. High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial). Br J Dermatol. 2024. PMID: 38913652. doi:10.1093/bjd/ljae257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。